Ipamorelin for Obesity: Does It Work?
Evidence-based review of Ipamorelin's effectiveness for obesity, including mechanism of action, dosage context, clinical data, and realistic expectations.
How Ipamorelin Addresses Obesity
Ipamorelin is a pentapeptide that selectively stimulates growth hormone (GH) secretion from the pituitary gland by activating ghrelin receptors (GHS-R1a). Unlike older GHRPs, it does not significantly increase cortisol or prolactin. This selectivity makes it favorable for body composition improvements, fat loss, muscle preservation, and recovery without the cortisol-related side effects of earlier secretagogues.
What Ipamorelin Is Primarily Used For
- 1.Growth hormone stimulation
- 2.Body composition improvement
- 3.Anti-aging
- 4.Sleep quality enhancement
- 5.Recovery optimization
What the Research Shows
Below is a summary of clinical evidence for Ipamorelin. Note that not all trials specifically study obesity as an endpoint.
Ipamorelin reliably stimulates GH secretion in a dose-dependent manner with high selectivity, producing minimal cortisol or prolactin elevations compared to GHRP-6 or GHRP-2.
Ipamorelin accelerated return of gut motility compared to placebo, suggesting utility beyond body composition.
Realistic Expectations
Dosage Context for Obesity
Typical range: 100–500 mcg, 1–3 times daily (often before bed and/or around workouts)
Commonly dosed at 200–300mcg per injection, 1–3 times daily. Best taken on an empty stomach to maximize GH pulse. Frequently combined with CJC-1295 or GHRH peptides for synergistic effect.
Doses for obesity may vary from general guidelines. Consult a healthcare provider for condition-specific dosing.
Legal Status & Access
Research chemical in the US. Not FDA approved. Available through peptide research suppliers.